Catching up on the Latest Horoscopes is an Indulgence for Sanjula Jain of Trilliant Health
Sanjula Jain, Ph.D., chief research officer at Trilliant Health, is one of 12 winners in this year's Emerging Leaders in Healthcare feature. In an interview with MHE, Jain shared that although she has an affinity for data-driven interpretations, she enjoys going down the rabbit hole of reading horoscope predictions and the personality descriptions of zodiac signs.
Sanjula Jain, Ph.D., chief research officer at Trilliant Health, is one of 12 winners in this year's Emerging Leaders in Healthcare feature. In an interview with MHE, Jain shared that although she has an affinity for data-driven interpretations, she enjoys going down the rabbit hole of reading horoscope predictions and the personality descriptions of zodiac signs.
In addition to what she claimed as a guilty pleasure, Jain shared advice that turned her career around, as well as a book and article she believe's those in healthcare should read.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More
